Vor Biopharma (NYSE:VOR) Price Target Lowered to $5.00 at Stifel Nicolaus

Vor Biopharma (NYSE:VOR - Free Report) had its price objective trimmed by Stifel Nicolaus from $12.00 to $5.00 in a report published on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Other research analysts also recently issued research reports about the stock. JMP Securities restated a "market outperform" rating and set a $12.00 price objective on shares of Vor Biopharma in a report on Tuesday, December 10th. Wedbush restated an "outperform" rating and issued a $7.00 target price on shares of Vor Biopharma in a report on Thursday, March 20th. Finally, HC Wainwright reiterated a "buy" rating and set a $17.50 price target on shares of Vor Biopharma in a research note on Tuesday, December 10th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $8.86.

Vor Biopharma Stock Performance

Shares of NYSE VOR traded down $0.04 during midday trading on Friday, hitting $0.85. 166,281 shares of the stock traded hands, compared to its average volume of 591,618. Vor Biopharma has a one year low of $0.63 and a one year high of $2.43. The business has a 50 day moving average price of $1.20 and a two-hundred day moving average price of $1.01. The company has a market cap of $58.19 million, a PE ratio of -0.51 and a beta of -0.40.

Remove Ads

Institutional Investors Weigh In On Vor Biopharma

A number of institutional investors have recently added to or reduced their stakes in VOR. Two Sigma Investments LP boosted its stake in shares of Vor Biopharma by 18.9% in the 4th quarter. Two Sigma Investments LP now owns 163,064 shares of the company's stock worth $181,000 after buying an additional 25,930 shares during the last quarter. Northern Trust Corp boosted its position in Vor Biopharma by 39.0% in the fourth quarter. Northern Trust Corp now owns 157,617 shares of the company's stock worth $175,000 after purchasing an additional 44,252 shares during the last quarter. Trustees of Columbia University in the City of New York purchased a new position in Vor Biopharma in the fourth quarter worth $102,000. RA Capital Management L.P. grew its stake in Vor Biopharma by 74.3% in the 4th quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company's stock valued at $44,007,000 after purchasing an additional 16,897,159 shares during the period. Finally, XTX Topco Ltd purchased a new stake in shares of Vor Biopharma during the 4th quarter valued at $80,000. 97.29% of the stock is owned by institutional investors.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.